61 related articles for article (PubMed ID: 10624422)
1. The correlation between cell surface markers and clinical features in choroidal malignant melanomas.
Lawry J; Currie Z; Smith MO; Rennie IG
Eye (Lond); 1999 Jun; 13 ( Pt 3a)():301-8. PubMed ID: 10624422
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous cell cycle and phenotypic analysis of primary uveal melanoma by flow cytometry.
Lawry J; Smith MO; Parsons MA; Rennie IG
Eye (Lond); 1998; 12 ( Pt 3a)():431-9. PubMed ID: 9775246
[TBL] [Abstract][Full Text] [Related]
3. Estimation of DNA content in uveal melanomas by flow cytometry.
Rennie IG; Rees RC; Parsons MA; Lawry J; Cottam D
Eye (Lond); 1989; 3 ( Pt 5)():611-7. PubMed ID: 2630338
[TBL] [Abstract][Full Text] [Related]
4. DNA index and % S phase fraction in posterior uveal melanoma: a 5 year prospective study of fresh tissue using flow cytometry.
Richardson RP; Lawry L; Rees RC; Rennie IG
Eye (Lond); 1997; 11 ( Pt 5)():629-34. PubMed ID: 9474308
[TBL] [Abstract][Full Text] [Related]
5. [The importance of flow cytometry and the cell proliferation index in choroidal melanoma].
Ranty ML; Quintyn JC; Courville P; Brasseur G
J Fr Ophtalmol; 2003 Sep; 26(7):725-9. PubMed ID: 13130261
[TBL] [Abstract][Full Text] [Related]
6. [DNA flow cytometry of malignant melanoma of the choroid].
Fuchs M; Wohlrab W; Klapperstück T; Fuchs U
Ophthalmologe; 1993 Oct; 90(5):496-500. PubMed ID: 8219639
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
8. HLA expression in choroidal melanomas: correlation with clinicopathological features.
Krishnakumar S; Abhyankar D; Lakshmi SA; Pushparaj V; Shanmugam MP; Biswas J
Curr Eye Res; 2004 Jun; 28(6):409-16. PubMed ID: 15512948
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas.
Isager P; Ehlers N; Overgaard J
Acta Ophthalmol Scand; 2004 Oct; 82(5):517-25. PubMed ID: 15453846
[TBL] [Abstract][Full Text] [Related]
10. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
11. Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma.
Béliveau A; Bérubé M; Rousseau A; Pelletier G; Guérin SL
Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2363-72. PubMed ID: 10892885
[TBL] [Abstract][Full Text] [Related]
12. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
13. Long term follow-up of c-myc, p53 and proliferation measurements in malignant melanoma.
Ross DA; Laing JH; Sanders R; Wilson GD
Eur J Surg Oncol; 2006 Feb; 32(1):80-4. PubMed ID: 16256294
[TBL] [Abstract][Full Text] [Related]
14. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
15. [Tumor markers in malignant choroid melanoma].
Scheiffarth OF; Strobl J; Stefani FH; Riedel KG; Scheidhauer K
Fortschr Ophthalmol; 1989; 86(6):639-43. PubMed ID: 2696716
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions.
Natali P; Nicotra MR; Cavaliere R; Bigotti A; Romano G; Temponi M; Ferrone S
Cancer Res; 1990 Feb; 50(4):1271-8. PubMed ID: 1967552
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric DNA analysis of primary cutaneous malignant melanoma.
Ohnishi K; Ishikawa H
Acta Derm Venereol; 1991; 71(6):525-8. PubMed ID: 1685836
[TBL] [Abstract][Full Text] [Related]
19. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
[TBL] [Abstract][Full Text] [Related]
20. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
